Indivior PLC (NASDAQ:INDV) Short Interest Update

Indivior PLC (NASDAQ:INDV) saw a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 1,420,000 shares, a growth of 17.4% from the January 15th total of 1,210,000 shares. Based on an average trading volume of 1,200,000 shares, the short-interest ratio is presently 1.2 days. Approximately 1.2% of the company’s shares are sold short.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rathbones Group PLC boosted its holdings in shares of Indivior by 11.6% in the fourth quarter. Rathbones Group PLC now owns 14,284 shares of the company’s stock valued at $183,000 after buying an additional 1,483 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Indivior by 4.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 41,327 shares of the company’s stock valued at $408,000 after acquiring an additional 1,888 shares in the last quarter. Stifel Financial Corp boosted its stake in Indivior by 24.0% in the 4th quarter. Stifel Financial Corp now owns 12,675 shares of the company’s stock worth $158,000 after purchasing an additional 2,450 shares during the period. PDT Partners LLC increased its holdings in Indivior by 4.7% during the 4th quarter. PDT Partners LLC now owns 57,520 shares of the company’s stock worth $715,000 after purchasing an additional 2,596 shares in the last quarter. Finally, Clark Estates Inc. NY raised its stake in shares of Indivior by 1.3% in the 4th quarter. Clark Estates Inc. NY now owns 257,400 shares of the company’s stock valued at $3,199,000 after purchasing an additional 3,300 shares during the period. 60.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on INDV shares. Rodman & Renshaw initiated coverage on Indivior in a research report on Tuesday, January 28th. They issued a “buy” rating and a $16.00 price target on the stock. RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a report on Tuesday, January 28th. Finally, Piper Sandler restated an “overweight” rating and set a $16.00 target price (up from $15.00) on shares of Indivior in a research report on Friday, October 25th.

Indivior Price Performance

Shares of INDV stock opened at $9.83 on Monday. Indivior has a 12-month low of $7.33 and a 12-month high of $23.22. The firm has a fifty day moving average of $11.63 and a 200-day moving average of $10.93.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.